(Q45628870)

English

Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy

scientific article published in May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy (English)

1 reference

Europe PubMed Central

14 December 2017

1 reference

based on heuristic

inferred from title

author name string

Nutthapong Tangsinmankong

1

1 reference

Europe PubMed Central

14 December 2017

Wasu Kamchaisatian

2

1 reference

Europe PubMed Central

14 December 2017

Noorbibi K Day

3

1 reference

Europe PubMed Central

14 December 2017

John W Sleasman

4

1 reference

Europe PubMed Central

14 December 2017

Patricia J Emmanuel

5

1 reference

Europe PubMed Central

14 December 2017

publication date

1 May 2004

1 reference

Europe PubMed Central

14 December 2017

Annals of Allergy, Asthma & Immunology

1 reference

Europe PubMed Central

14 December 2017

92

1 reference

Europe PubMed Central

14 December 2017

5

1 reference

Europe PubMed Central

14 December 2017

558-564

1 reference

Europe PubMed Central

14 December 2017

American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Invasive pneumococcal infections in human immunodeficiency virus-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical indicators of immune restoration following highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody deficiency syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of host defense against infection with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of the antibody response to pneumococcal vaccine in high-risk populations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pneumococcal vaccine in normal children. Primary and secondary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Six year multicenter surveillance of invasive pneumococcal infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Invasive pneumococcal disease in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961764-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1081-1206(10)61764-4

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45628870&oldid=2077442934"